768 Hodgkin's disease (HD), clinical stages (CS) IA-IIIB without bulky tumor: Interim results of the goelams randomized H90-NM protocol

From 2/90 to 6/93, 195 adult patients (pts) with HD, CS IA-IIIB without bulky tumor (nodes 2 : adriamycin 25, bleomycin (BLM) 10, vinblastin (VBL) 6, dacarbazin 375, methylprednisolone (MP) 120 = arm A, 101 pts) or EBVM-MP (Dl and D15, mg/m 2 : epirubicin 30, BLM 10, VBL 6, methotrexate 30, MP 120 = arm E, 94 pts). CT-responding pts were given (sub)total nodal and splenic RT (involved fields 40 Gy, non-involved 30 Gy). Pts characteristics: M 110, F 85; age 40 47; CS I 56, II 117, HI 22; A 152, B 43; histology: LP 21, NS 128, MC 30, LD 1, UN 15. Complete remission rates after CT and RT were 81% (A 83 pts, E 74 pts) and 95% (A 96 pts, E 90 pts) ( P  = NS); 10 pts relapsed (A 1, E 9, P